Prothena Corporation plc
Prothena Corporation plc
Your view on PRTA
Overview
What the company does, where it operates, and who runs it.
About Prothena Corporation plc
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Gene G. Kinney
- Headquarters
- 77 Sir John Rogerson’s Quay, Dublin, IE
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Gene G. Kinney
- Headquarters
- 77 Sir John Rogerson’s Quay, Dublin, IE
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States.
The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease.
Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies.
The company was founded in 2012 and is based in Dublin, Ireland.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Prothena Corporation plc from FRC's valuation model, read against the market price. PRTA last traded at $7.97; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Prothena Corporation plc. Starting points for Prothena Corporation plc: EPS -$0.47, beta -0.33 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Prothena Corporation plc. Prothena Corporation plc does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Prothena Corporation plc. Trailing twelve-month EPS for Prothena Corporation plc stands at -$0.47. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$21.75
average of 4 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy20
- Hold6
- Sell2
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $0.02 | -$0.37 | -$0.02 | -$1.02 |
| Low estimate | $0.01 | -$0.38 | -$0.15 | -$1.36 |
| High estimate | $0.03 | -$0.36 | $0.11 | -$0.40 |
| No. of analysts | 2 | 1 | 4 | 4 |
| Year-ago EPS | -$0.44 | $0.601 | -$4.53 | — |
| Growth | +105.5% | — | +99.5% | — |
1Year-ago EPS includes one-time items; growth not shown.
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $19.92M | $581169.00 | $72.42M | $24.54M |
| Low estimate | $451006.00 | $13160.00 | $47.98M | $19.74M |
| High estimate | $39.37M | $1.15M | $96.88M | $31.59M |
| No. of analysts | 4 | 2 | 5 | 5 |
| Year-ago revenue | $21000.00 | $51.08M | $9.68M | — |
| Growth | +94737.4% | -98.9% | +647.9% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Prothena Corporation plc. Prothena Corporation plc has reported as a listed company since 2012. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ABOSAcumen Pharmaceuticals, Inc.Biotechnology$16M
- ACIUAC Immune S.A.Biotechnology$213M
- ANNXAnnexon, Inc.Biotechnology$585M
- AVXLAnavex Life Sciences Corp.Biotechnology$76M
- BIIBBiogen Inc.Drug Manufacturers - General$37.2B
- CGTXCognition Therapeutics, Inc.Biotechnology$61M
- DNLIDenali Therapeutics Inc.Biotechnology$2.9B
- NMRANeumora Therapeutics, Inc. Common StockBiotechnology$69M
More Biotechnology companies
- OCSOculis Holding AGNASDAQ$471M
- MGNXMacroGenics, Inc.NASDAQ$139M
- MGTXMeiraGTx Holdings plcNASDAQ$854M
- MGXMetagenomi, Inc. Common StockNASDAQ$26M
- MIR.VMedMira Inc.TSXV$16M
- MIRMMirum Pharmaceuticals, Inc.NASDAQ$6.0B
- MISTMilestone Pharmaceuticals Inc.NASDAQ$45M
- MLECMoolec Science S.A.NASDAQ$617,200
- MLECWMoolec Science S.A.NASDAQ$76,243
- MLLCFMolecular Partners AGOTC$131M
- MLTXMoonLake ImmunotherapeuticsNASDAQ$998M
- MLYSMineralys Therapeutics, Inc.NASDAQ$1.3B
ETFs holding Prothena Corporation plc
% of the fund
- IWMiShares Russell 2000 ETF$76.6B in assets0.01%
- XBIState Street SPDR S&P Biotech ETF$10.0B in assets0.08%
- VXFVanguard Extended Market ETF$30.2B in assets0.00%
- DFASDimensional - US Small Cap ETF$33.7B in assets0.01%
- BBCVirtus LifeSci Biotech Clinical Trials ETF$32M in assets0.79%
- QQQSInvesco NASDAQ Future Gen 200 ETF$20M in assets0.52%
- FSCCFederated Hermes MDT Small Cap Core ETF$496M in assets0.41%
- GSSCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETF$1.0B in assets0.04%
Largest holders first, then the funds most concentrated in PRTA.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Prothena Corporation plc, and how their positions are changing. At a $409.3M market value, institutional positions materially move Prothena Corporation plc's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Prothena Corporation plc executives and directors. Shares of Prothena Corporation plc have traded between $4.32 and $17.66 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Prothena Corporation plc. Coverage tracks Prothena Corporation plc within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Prothena Corporation plc.